On September 7, 2021 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that Laurent Levy, Chief Executive Officer, will present the Company’s latest corporate and clinical developments during a webcast at the virtual H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Nanobiotix, SEP 7, 2021, View Source [SID1234587299]). The presentation will be available on-demand starting at 7:00 AM EDT / 1:00 PM CET on Monday, September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the event will be available for 90 days on the events section of the Company’s website.

On September 7, 2021 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021 (Press release, Aileron Therapeutics, SEP 7, 2021, View Source [SID1234587298]). Dr. Aivado’s presentation will include an update on the company’s progress advancing ALRN-6924 as a selective chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An on-demand corporate presentation will be accessible to registered conference attendees starting on Monday, September 13, 2021 at 7 am ET. A recorded webcast of the presentation will be archived under the Investors and Media section of Aileron’s website at View Source for 30 days following the event. Aileron management will conduct one-on-one meetings with investors during the conference.

On September 7, 2021 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. PT on Monday, September 13, 2021 (Press release, Sana Biotechnology, SEP 7, 2021, View Source [SID1234587297]). The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.

On September 7, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Revolution Medicines, SEP 7, 2021, View Source [SID1234587296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

H.C. Wainwright 23rd Annual Global Investment Conference
Conference Dates: September 13-15, 2021
Presentation Timing: 7:00 a.m. Eastern on Monday, September 13, 2021
Format: Virtual conference; webcast available
To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On September 7, 2021 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, reported that the Company’s management will participate in two upcoming investor conferences in September (Press release, Corvus Pharmaceuticals, SEP 7, 2021, View Source [SID1234587295]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first conference is the H.C. Wainwright Annual Global Investment Conference, which is taking place September 13-15, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 13. Attendees can register to view the webcast here.

The second conference is the Cantor Virtual Global Healthcare Conference, which is taking place September 27-30, 2021. The Company will conduct one-on-one meetings with investors at this conference and a virtual corporate overview presentation will be conducted by Dr. Miller at 3:20-3:50 pm ET on September 29. Attendees can register for the virtual presentation here.
Attendees can also access the webcast of the presentations noted above via the investor relations section of the Corvus website and replays will be available for 90 days following the events.